-
2023-503170-20-01
1
2024-02-26
Advanced solid tumors
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2023-505346-26-01
7
2024-02-19
9 main solid tumors – colorectal, cervical, endometrial, gastric, urot
-
2023-507367-18-00
6
2024-02-14
Pancreatic exocrine insufficiency
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2023-509142-35-00
6
2024-01-29
Atrial fibrillation after stress (e.g., noncardiac surgery or acute me
-
2022-502413-29-00
4
2024-01-22
BRAF V600E mutated and microsatellite stable (MSS) advanced colorectal
-
2023-506572-27-00
3
2024-01-12
Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD)
-
2023-505911-19-00
4
2024-01-05
Acute Myeloid Leukemia
-
2023-503665-39-00
4
2023-11-14
Advanced cholangiocarcinoma
-
2023-503495-24-00
1
2023-10-30
Hormone-refractory prostate cancer
-
2023-504845-30-00
7
2023-10-05
Solid malignancies
-
2022-502160-20-00
5
2023-10-02
Idiopathic Immune Complex Mediated Membranoproliferative Glomeruloneph
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2023-503373-37-01
4
2023-09-11
Premenopausal women with early luminal breast cancer
-
2024-510959-35-00
4
2023-09-07
Parkinson's disease
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease
-
2022-500801-41-00
1
2023-07-26
Relapsed and Refractory Multiple Myeloma
-
2023-503613-29-00
4
2023-07-18
Laparoscopic hepatectomy surgery
-
2022-502156-31-00
9
2023-05-26
Glioblastoma
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2022-502051-56-00
5
2023-04-28
H3 K27M-mutant diffuse glioma